More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

For those using these products for weight loss only, it’s important to understand that these are not miracle drugs.

Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...

Ozempic, along with its sister drug Wegovy, belongs to a new class of therapeutic known as GLP-1 receptor agonists. Originally developed for diabetes management, these medications have found a ...

Another day, another headline suggesting the new breed of diabetes and weight loss drugs offer hope for another chronic ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

and have been reaping the rewards of supplying versions of Novo Nordisk's obesity drug Wegovy and Ozempic for diabetes, which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

While Ozempic bodes well for weight loss, some users are concerned the drug's impact also means unwanted changes to their ...